| abstract |
This invention is in the area of improved colorectal cancer treatment protocols that provide reduced toxicity compared to currently used regimens, including reduced chemotherapy -induced myelosuppression (CIM), diarrhea, mucositis, and/or stomatitis, while, in some embodiments, also improving anti-cancer efficacy. The improved protocols incorporate a highly selective, transient cyclin dependent kinase (CDK) 4/6 inhibitor into the colorectal cancer treatment protocol, allowing for the expanded use of effective fluorouracil-based multi-agent chemotherapies, for example FOLFOXIRI or FOLFIRINOX, into patient populations previously excluded from these protocols. |